Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 10/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15051277 | 0.85 | AAK1 (0.43) | AAK1CYP3A4PIK3C3MAPK14GSK3B | |
| SCHEMBL15051361 | 0.81 | NR3C2 (0.42) | AAK1CYP3A4PIK3C3NPC1MAPK10 | |
| SCHEMBL15050034 | 0.80 | PIK3C3 (0.41) | AAK1CYP3A4PIK3C3MAPK14GSK3B | |
| SCHEMBL25252267 | 0.74 | PIK3C3 (0.40) | AAK1CYP3A4PIK3C3MAPK14MAPK10 | |
| SCHEMBL15051452 | 0.74 | NPC1 (0.48) | NPC1 | |
| SCHEMBL15050049 | 0.74 | PIK3C3 (0.40) | AAK1CYP3A4PIK3C3MAPK14MAPK10 | |
| SCHEMBL15050234 | 0.73 | MAPK14 (0.41) | AAK1CYP3A4PIK3C3MAPK14MAPK10 | |
| SCHEMBL15050084 | 0.73 | CNR1 (0.40) | AAK1CYP3A4PIK3C3MAPK14MAPK10 | |
| SCHEMBL25235193 | 0.73 | MAPK14 (0.41) | MAPK14MAPK10 | |
| SCHEMBL25207714 | 0.72 | MAPK14 (0.41) | AAK1CYP3A4MAPK14MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2793879-A1 | HETEROARYLS AND USES THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013096637-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | PIK3R5, PIK3R4, PIK3C2B | AAK1 3261/4885CYP3A4 769/4885PIK3C3 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.